Alpha Tau Medical (DRTS) Cash & Equivalents (2020 - 2026)

Alpha Tau Medical (DRTS) has 7 years of Cash & Equivalents data on file, last reported at $4.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 7.63% year-over-year to $4.6 million; the trailing twelve-month figure through Mar 2026 stood at $4.6 million (down 7.63% YoY), and the FY2025 full-year result was $12.2 million, down 11.09% from the prior year.
• Cash & Equivalents retreated to $4.6 million in Q1 2026, from $12.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $98.9 million in Q1 2022 to a low of $82000.0 in Q3 2023.
• A 5-year average of $12.0 million and a median of $5.8 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents sank 99.09% in 2023 and surged 6639.02% in 2024, its largest moves.
• Tracing DRTS's Cash & Equivalents over 5 years: stood at $5.8 million in 2022, then soared by 116.88% to $12.7 million in 2023, then increased by 8.43% to $13.7 million in 2024, then decreased by 11.09% to $12.2 million in 2025, then plunged by 62.01% to $4.6 million in 2026.
• Business Quant data shows DRTS's Cash & Equivalents at $4.6 million in Q1 2026, $12.2 million in Q4 2025, and $3.3 million in Q3 2025.